Cargando…

Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia

INTRODUCTION: : Access to combination antiretroviral treatment (cART) and toxicity profiles of antiretroviral medications have significantly improved during the last three decades. In order to optimise treatment outcomes, achieve favourable virological suppression and immunological status, balanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Kušić, Jovana, Mladenović, Milana, Dimitrijević, Božana, Aleksić, Branka, Zec, Simon, Jevtović, Djordje, Dragović Lukić, Gordana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946693/
https://www.ncbi.nlm.nih.gov/pubmed/27482433
_version_ 1782443058529304576
author Kušić, Jovana
Mladenović, Milana
Dimitrijević, Božana
Aleksić, Branka
Zec, Simon
Jevtović, Djordje
Dragović Lukić, Gordana
author_facet Kušić, Jovana
Mladenović, Milana
Dimitrijević, Božana
Aleksić, Branka
Zec, Simon
Jevtović, Djordje
Dragović Lukić, Gordana
author_sort Kušić, Jovana
collection PubMed
description INTRODUCTION: : Access to combination antiretroviral treatment (cART) and toxicity profiles of antiretroviral medications have significantly improved during the last three decades. In order to optimise treatment outcomes, achieve favourable virological suppression and immunological status, balanced with potential adverse effects of cART, it is considered beneficial to maintain first-line antiretroviral treatment for as long as possible. However, the Republic of Serbia, as a resource-limited setting, often experiences interruptions to drug supplies. Data are very limited in Serbia concerning the initial antiretroviral regimens prescribed and the reasons for treatment changes. AIMS: : The aim of this study was to determine the most frequently prescribed antiretroviral drugs within first-line cART regimens in drug-naïve patients in Serbia and the reasons for switching drugs. METHODS: : All HIV-infected individuals who started cART at the HIV/AIDS Center of Infectious and Tropical Diseases, Clinical Centre of Serbia, from 1 January 2004 until 1 July 2014 were included. A cohort of 339 patients were retrospectively analysed to review their initial treatment regimens. All analyses were performed using the SPSS statistical package version 11.0. Descriptive measurements and Kaplan–Meier survival curves were used. RESULTS: : The most frequently prescribed nucleoside reverse transcriptase inhibitor (NRTI) backbones in the cART regiment were fixed combinations of abacavir and lamivudine (n=181, 53.3%) and of zidovudine and lamivudine (n=103, 30.5%). Efavirenz was the most commonly prescribed ‘third’ drug (n=254, 75%). Where given, reasons for switching initial cART were shortage of antiretroviral drugs (e.g. out of stock, n=53, 37.6%), toxicity (n=49, 34.3%), physician choice (n=21, 14.6%), resistance (n=15, 10.6%), and patient choice (n=4, 2.9%). Mean duration of first-line cART was 20±17 months. CONCLUSION: : The most frequently prescribed initial cART regimen in Serbia is not the preferred first choice, but an alternative option according to the international antiretroviral treatment guidelines. Duration of first-line cART is short and a switch to second-line cART is often made due to a shortage of antiretroviral medications and the more severe side effects resulting from the use of older drugs.
format Online
Article
Text
id pubmed-4946693
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Mediscript Ltd
record_format MEDLINE/PubMed
spelling pubmed-49466932016-08-01 Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia Kušić, Jovana Mladenović, Milana Dimitrijević, Božana Aleksić, Branka Zec, Simon Jevtović, Djordje Dragović Lukić, Gordana J Virus Erad Original Research INTRODUCTION: : Access to combination antiretroviral treatment (cART) and toxicity profiles of antiretroviral medications have significantly improved during the last three decades. In order to optimise treatment outcomes, achieve favourable virological suppression and immunological status, balanced with potential adverse effects of cART, it is considered beneficial to maintain first-line antiretroviral treatment for as long as possible. However, the Republic of Serbia, as a resource-limited setting, often experiences interruptions to drug supplies. Data are very limited in Serbia concerning the initial antiretroviral regimens prescribed and the reasons for treatment changes. AIMS: : The aim of this study was to determine the most frequently prescribed antiretroviral drugs within first-line cART regimens in drug-naïve patients in Serbia and the reasons for switching drugs. METHODS: : All HIV-infected individuals who started cART at the HIV/AIDS Center of Infectious and Tropical Diseases, Clinical Centre of Serbia, from 1 January 2004 until 1 July 2014 were included. A cohort of 339 patients were retrospectively analysed to review their initial treatment regimens. All analyses were performed using the SPSS statistical package version 11.0. Descriptive measurements and Kaplan–Meier survival curves were used. RESULTS: : The most frequently prescribed nucleoside reverse transcriptase inhibitor (NRTI) backbones in the cART regiment were fixed combinations of abacavir and lamivudine (n=181, 53.3%) and of zidovudine and lamivudine (n=103, 30.5%). Efavirenz was the most commonly prescribed ‘third’ drug (n=254, 75%). Where given, reasons for switching initial cART were shortage of antiretroviral drugs (e.g. out of stock, n=53, 37.6%), toxicity (n=49, 34.3%), physician choice (n=21, 14.6%), resistance (n=15, 10.6%), and patient choice (n=4, 2.9%). Mean duration of first-line cART was 20±17 months. CONCLUSION: : The most frequently prescribed initial cART regimen in Serbia is not the preferred first choice, but an alternative option according to the international antiretroviral treatment guidelines. Duration of first-line cART is short and a switch to second-line cART is often made due to a shortage of antiretroviral medications and the more severe side effects resulting from the use of older drugs. Mediscript Ltd 2016-01-01 /pmc/articles/PMC4946693/ /pubmed/27482433 Text en © 2016 The Authors. Journal of Virus Eradication published by Mediscript Ltd http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article published under the terms of a Creative Commons License.
spellingShingle Original Research
Kušić, Jovana
Mladenović, Milana
Dimitrijević, Božana
Aleksić, Branka
Zec, Simon
Jevtović, Djordje
Dragović Lukić, Gordana
Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title_full Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title_fullStr Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title_full_unstemmed Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title_short Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia
title_sort treatment outcomes of first-line antiretroviral therapy in hiv-1-positive patients in serbia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946693/
https://www.ncbi.nlm.nih.gov/pubmed/27482433
work_keys_str_mv AT kusicjovana treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT mladenovicmilana treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT dimitrijevicbozana treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT aleksicbranka treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT zecsimon treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT jevtovicdjordje treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia
AT dragoviclukicgordana treatmentoutcomesoffirstlineantiretroviraltherapyinhiv1positivepatientsinserbia